Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fujian Aonong Biological Technology Grouporp's quarterly Total Liabilities
declined
from Sep. 2025 (¥5,362.98 Mil) to Dec. 2025 (¥5,161.73 Mil) but then
increased
from Dec. 2025 (¥5,161.73 Mil) to Mar. 2026 (¥5,341.03 Mil).
Fujian Aonong Biological Technology Grouporp's annual Total Liabilities
declined
from Dec. 2023 (¥14,128.43 Mil) to Dec. 2024 (¥6,444.95 Mil) and
declined
from Dec. 2024 (¥6,444.95 Mil) to Dec. 2025 (¥5,161.73 Mil).
Fujian Aonong Biological Technology Grouporp Total Liabilities Related Terms
Fujian Aonong Biological Technology Grouporp Total Liabilities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Aonong Biological Technology Grouporp Total Liabilities Chart
Fujian Aonong Biological Technology Grouporp Annual Data
Fujian Aonong Biological Technology Grouporp Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Aonong Biological Technology Grouporp (SHSE:603363) has a Total Liabilities of ¥5,341 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Fujian Aonong Biological Technology Grouporp and its competitors.
Is Fujian Aonong Biological Technology Grouporp's Total Liabilities too high?
Fujian Aonong Biological Technology Grouporp's current Total Liabilities is ¥5,341 Mil. Overall, Fujian Aonong Biological Technology Grouporp has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fujian Aonong Biological Technology Grouporp's Total Liabilities compare to ADM and BG?
Fujian Aonong Biological Technology Grouporp's Total Liabilities of ¥5,341 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Consumer Packaged Goods company?
A good Total Liabilities depends on the Consumer Packaged Goods industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Fujian Aonong Biological Technology Grouporp and its competitors. Fujian Aonong Biological Technology Grouporp's current Total Liabilities is ¥5,341 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fujian Aonong Biological Technology Grouporp stock overvalued right now?
Based on GuruFocus' analysis, Fujian Aonong Biological Technology Grouporp (SHSE:603363) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥1.32, compared to a current price of ¥2.67 — trading 102.3% above its estimated fair value. The current Total Liabilities is ¥5,341 Mil. Fujian Aonong Biological Technology Grouporp's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Fujian Aonong Biological Technology Grouporp (SHSE:603363), the current Total Liabilities is ¥5,341 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fujian Aonong Biological Technology Grouporp (SHSE:603363) Overvalued in 2026?
Based on GuruFocus' analysis, Fujian Aonong Biological Technology Grouporp stock appears to be overvalued.
The current stock price of ¥2.67 is trading 102.3% above its estimated GF Value™ of ¥1.32.
GuruFocus considers Fujian Aonong Biological Technology Grouporp to be Significantly Overvalued.
Key valuation signals for SHSE:603363:
Total Liabilities: ¥5,341 Mil
GF Value™: ¥1.32 vs. price of ¥2.67 (102.3% above fair value)
No single metric tells the full story. See the SHSE:603363 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fujian Aonong Biological Technology Grouporp Business Description
Fujian Aonong Biological Technology Group Incorp Ltd is an agricultural and animal husbandry enterprise in China. The principal business activities of the company include feed-oriented service, animal protection, pig raising, and raw material trade. In addition, the company's insurance business mainly relies on the feed marketing system throughout the country to provide downstream farmers with relevant products for disease prevention and control.
31GF Score
Get the complete analysis for SHSE:603363
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603363 has been successfully added to your 
